New injection method aims to make opioid addiction treatment easier to start
NCT ID NCT06441604
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study tests whether a long-acting buprenorphine injection can be used to start treatment for opioid use disorder without causing severe withdrawal. Thirty adults with opioid use disorder will stay in a hospital for three days, receive fentanyl to prevent withdrawal, and then get one injection of extended-release buprenorphine at different doses. Researchers will monitor safety and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
extended-release buprenorphine injection
What this could lead to
If successful, this could offer a safer, more comfortable way to start buprenorphine treatment for opioid use disorder, reducing the risk of severe withdrawal symptoms.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. There is a risk of precipitated withdrawal despite the use of fentanyl.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02118-5605, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••